BIOASTER announces the kick off a new IMI project “GNA NOW” (Gram-Negative Antibacterials NOW), led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI), a public-private european R&D consortium. The program will work on the development of novel antibacterial agents to battle antimicrobial resistance...

BIOASTER announced the signature of a collaboration agreement with Pherecydes Pharma, a French Biotechnology company, with the objective of discovering lytic bacteriophages, to be developed...